Mood Disorders News

Adverse childhood experiences, particularly those that occurred during the prepubertal phase, increased risk for incident menopause major depressive disorder.

Rutgers University Behavioral Health Care recently launched four intensive outpatient programs focusing on substance use and mood disorders.

Once-daily valbenazine, a selective vesicular monoamine transporter 2 inhibitor, significantly improved tardive dyskinesia in individuals with schizophrenia, schizoaffective disorder or mood disorder.

Takeda Pharmaceuticals and Cognition Kit Limited recently announced a collaborative study assessing efficacy of an Apple Watch app to monitor and assess cognitive function in major depressive disorder.

Individuals with intermittent explosive disorder had increased risk for substance use disorders, which suggests aggressive behavior may be an indicator of substance use disorder risk.

Sunovion recently announced positive phase 3 study findings for Latuda for bipolar I disorder depression in children aged 10 to 17 years.

Exposure to maternal depression during preschool years was more harmful to children’s psychological development than perinatal exposure.

A recent consensus statement in JAMA Psychiatry reviewed available research on the use of ketamine for psychiatric indications and provided recommendations for clinicians considering or currently administering ketamine.

Tiredness is partially heritable and heterogenous, and phenotypically and genetically associated with affective, cognitive, personality and physiological disorders, according to recent findings.

Postpartum depressive symptoms decreased from 2004 to 2012, but remain prevalent among women in the U.S., according to CDC data.